Pharmaceutical Manufacturers: Antibiotics/Vitamins/Injections

I. Customer Pain Points

Pharmaceutical companies (producing antibiotics, vitamins, and injectables) face three major challenges during the synthesis, purification, and sterilization processes: difficulty in removing pyrogens, loss of active pharmaceutical ingredients, and residual organic solvents, all of which directly threaten drug safety and compliance.

Incomplete removal of the heat source (endotoxin) poses significant drug safety risks.

The fermentation broth of antibiotics (e.g., penicillin) contains bacterial endotoxins (concentration 10–50 EU/mL), while the refined solution of vitamins (e.g., vitamin C) contains pyrogens (concentration 5–30 EU/mL). Prior to filling injections, these products must comply with the requirements of the China Pharmacopoeia 2020 edition ("Endotoxin in water for injection ≤ 0.25 EU/mL") and the US FDA 21 CFR Part 211 ("Endotoxin in injections ≤ 0.5 EU/mL"). Traditional high-temperature sterilization (121°C, 30 min) can only inactivate bacteria but cannot eliminate free endotoxins and may degrade heat-sensitive components (e.g., vitamin C degradation rate>20%). A penicillin manufacturer collaborating with Shanxi Xinhua Carbon Technology once recalled 100,000 doses of injections due to excessive endotoxin levels (0.8 EU/mL), resulting in losses exceeding 2 million yuan.

Loss of active ingredients, resulting in insufficient efficacy

The conventional "activated carbon decolorization" process for vitamins (e.g., vitamin B₁₂, molecular diameter ≈ 0.7 nm) and antibiotics (e.g., cephalosporins, ≈ 0.8 nm) was not optimized for target molecules, resulting in an effective ingredient adsorption loss rate exceeding 15% and a drug活性 component content below 90% (falling short of the EU EMA guideline requirement of "≥95% active ingredient in injections"). A vitamin C manufacturer collaborating with Shanxi Xinhua Carbon Technology incurred annual losses exceeding ¥800,000 due to this issue.

Residual organic solvents: environmental and safety risks

Methanol (concentration 500–2000 mg/L), acetone (concentration 300–1500 mg/L), and ethanol for vitamin extraction (concentration 1000–5000 mg/L) used in antibiotic synthesis must comply with the following requirements: organic solvents ≤50 mg/m³ as specified in China GB 21905-2008 "Emission Standards for Air Pollutants from Pharmaceutical Industry" and residual solvents ≤500 ppm per ICH Q3C; traditional condensation recovery methods achieve a removal rate of less than 40% for low-concentration solvents, resulting in annual environmental fines of up to 300,000 yuan per enterprise (2022 industry data); additionally, these solvents pose explosion risks (methanol's explosive limit ranges from 5.5% to 44%).

II. Application Objectives

Pharmaceutical companies adopt activated carbon for four core objectives: eliminating heat sources, preserving active ingredients, recovering solvents, and ensuring compliance.

Thoroughly eliminate heat sources to ensure drug safety

Using medical-grade granular activated carbon (GAC, Φ2–5 mm, specific surface area 1000–1200 m²/g) to precisely adsorb bacterial endotoxins (molecular weight 1–10 kDa via pore retention and surface adsorption), the removal rate exceeds 99.5%, reducing endotoxin levels to <0.1 EU/mL (exceeding the requirements of China Pharmacopoeia 2020 edition and FDA 21 CFR Part 211). After application at a penicillin factory collaborating with Shanxi Xinhua Carbon Technology, the endotoxin exceedance rate dropped from 15% to zero, avoiding potential recall losses.

Preserves active ingredients to ensure therapeutic efficacy

Using mesoporous activated carbon (with 50% particles sized 2–50 nm) to adsorb impurities (e.g., proteins ≈5 nm, pigments ≈0.8 nm) while retaining active components such as vitamin B₁₂ (≈0.7 nm) and cephalosporins (≈0.8 nm), the effective component loss rate is <3%, with content increased to>98% (compliant with EU EMA guidelines). When implemented at a vitamin C factory collaborating with Shanxi Xinhua Carbon Technology, the effective component loss was reduced from 18% to 2%, resulting in annual cost savings of ¥750,000.

Highly efficient recovery of organic solvents for cost reduction and enhanced safety

Hydrophobic activated carbon (loaded with hydrophobic groups) was employed to adsorb methanol, acetone, and ethanol, achieving an adsorption capacity of 300–500 mg solvent/g carbon (twice that of conventional activated carbon) and a recovery rate exceeding 98% (with concentration reduced to <10 mg/m³, compliant with GB 21905-2008). When implemented by a cooperative antibiotic manufacturer of Shanxi Xinhua Carbon Technology, the organic solvent recovery value exceeded ¥500,000 annually, while annual environmental fines were reduced from ¥300,000 to zero.

Strict compliance enables breakthroughs in the international market.

Complies with global pharmaceutical industry standards:

China Pharmacopoeia 2020 Edition: Endotoxin in Water for Injection ≤0.25 EU/mL, microbial limit ≤100 CFU/mL;

US FDA 21 CFR Part 211: Endotoxin levels in injections ≤ 0.5 EU/mL; residual solvents ≤ the limit specified in ICH Q3C.

EUEMA Guidelines: Active ingredient content ≥95%, pyrogen removal rate>99%.

III. Application Significance

The application of activated carbon in pharmaceutical enterprises serves as the core foundation for achieving "safety baseline, efficacy assurance, and international market compliance."

Safety baseline: Approximately 50% of global injectable drug recall incidents are attributed to excessive endotoxin levels. Activated carbon represents one of the few technologies capable of simultaneously removing endotoxins while preserving heat-sensitive components, thereby directly preventing drug recalls (as demonstrated by a penicillin manufacturer collaborating with Shanxi Xinhua Carbon Technology, which avoided annual losses of 2 million yuan following its use).

Drug efficacy assurance: The loss rate of active ingredients was reduced from 15% to <3%. A vitamin manufacturer serving as a cooperative client of Shanxi Xinhua Carbon Technology achieved an annual increase in drug efficacy value of 750,000 yuan, equivalent to a 2 percentage point improvement in gross profit margin.

International regulatory requirements: The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) impose stringent standards for injectable formulations, demanding that active ingredients account for ≥95% and endotoxin levels be ≤0.5 EU/mL. The activated carbon process remains the only cost-effective technology capable of meeting these requirements. Following its implementation by a pharmaceutical company, antibiotic injection exports to the EU increased from 50,000 vials per month to 200,000 vials per month.

IV. Application History

The application of activated carbon in pharmaceutical enterprises has been progressively deepened alongside the upgrading of injection safety standards and stricter controls on organic solvents.

1970s: Initial Stage

Pfizer in the United States was the first to treat penicillin fermentation broth (containing 20 EU/mL of endotoxins) with medical-grade powdered activated carbon (PAC, 100 mesh), reducing endotoxin levels to 0.2 EU/mL through an "adsorption-filteration" process, marking the world's inaugural case of using activated carbon to eliminate pyrogenic contaminants from injectables.

2020s: The Intelligent Phase

China's "14th Five-Year Plan for the Pharmaceutical Industry Development" requires that the recovery rate of organic solvents be ≥95%. Activated carbon, combined with an "online endotoxin monitoring + automatic adsorption" system, enables precise removal (e.g., automatically adjusting GAC dosage based on endotoxin concentrations in fermentation broth) and reduces operating costs by 25%.

V. Mechanism of Action

Through a triple mechanism of "physical adsorption + chemical modification + pore sieving," activated carbon addresses the challenges in pharmaceutical production related to "heat source removal, active ingredient retention, and solvent recovery."

1. Physical adsorption: "Targeted retention" via porous structure

Mesopores (2–50 nm): Accounting for 50% of the total pore volume (specifically designed for pharmaceutical molecules), these pores adsorb medium-sized molecular impurities (proteins ≈5 nm, pigments ≈0.8 nm) via van der Waals forces, with an adsorption capacity of 200–300 mg of impurities per g of carbon; simultaneously, the pore size filtration effectively retains bacterial endotoxins (molecular weight 1–10 kDa, size>2 nm) with a removal rate exceeding 99.5%.

Microholes (<2 nm): Serving as "deep purification channels," they adsorb small molecular solvents (methanol ≈ 0.4 nm, acetone ≈ 0.5 nm) with an adsorption capacity of 300–500 mg solvent/g of hydrophobic activated carbon.

Macropores (>50 nm): Serving as an "entry channel" that allows large molecular suspended particles (>1 μm) to enter the activated carbon interior, thereby reducing subsequent filtration load.

2. Chemical modification: "precise retention" of surface functional groups

The hydroxyl (-OH) and carboxyl (-COOH) groups on the activated carbon surface repel vitamin B₁₂ (≈0.7 nm, positively charged) and cephalosporins (≈0.8 nm, weakly acidic) via electrostatic repulsion, preventing adsorption and ensuring an active ingredient retention rate>97% (compared to 85% with conventional PAC).

3. Hydrophobic modification: "solvent adsorption" of surface functional groups

The hydrophobic groups (e.g., methyl group-CH₃) loaded on the activated carbon surface adsorb methanol, acetone, and ethanol (hydrophobic solvents) via hydrophobic interactions, achieving an adsorption capacity of 300–500 mg/g (twice that of conventional activated carbon) with a recovery rate exceeding 98%.

VI. Application Methods

Pharmaceutical companies employ a combined process of "pyrogen removal from fermentation broth (GAC) + active ingredient purification (mesoporous GAC) + organic solvent recovery (hydrophobic GAC)" to cover all application scenarios for antibiotics, vitamins, and injectables.

1. Remove pyrogens from fermentation broth/refined solution: Medical-grade GAC fixed bed

Application scenarios: Penicillin fermentation broth (endotoxin level 10–50 EU/mL), refined vitamin C solution (pyrogen level 5–30 EU/mL; endotoxin content must be <0.25 EU/mL).

process sequence ：

Pre-treatment: Fermentation broth → Filtration (to remove mycelium, SS ≤ 10 mg/L); Purified solution → Ultrafiltration (with a molecular weight cut-off of 10 kDa to eliminate large-molecule proteins).

GAC adsorption: The feed solution enters a medical-grade GAC fixed bed (Φ2–5 mm, specific surface area 1000–1200 m²/g, ash content ≤0.5%), with a flow rate of 5–10 m/h and a contact time of 20–30 minutes, achieving an endotoxin removal rate>99.5% (reduced to <0.1 EU/mL).

2. Active ingredient purification: mesoporous GAC fixed bed

Application scenarios: Vitamin B12 refined solution (active ingredient content 92%, required ≥98%) and cephalosporin synthesis solution (active ingredient content 90%, required ≥95%).

process sequence ：

Refined solution → Medium-pore GAC fixed bed (Φ3–6 mm, with medium-pore particles accounting for 50%, specific surface area 900–1100 m²/g), flow rate 5–8 m/h, contact time 25 minutes → Active ingredient content>98% (vitamin B₁₂) and>98.5% (cephalosporin), adsorption loss rate <3%.

3. Organic solvent recovery: Hydrophobic GAC adsorption tower

Application scenarios: Antibiotic synthesis exhaust gases (methanol 500–2000 mg/m³, acetone 300–1500 mg/m³); vitamin extraction exhaust gases (ethanol 1000–5000 mg/m³, with a maximum concentration of ≤50 mg/m³).

process sequence ：

Exhaust gas → Condensation (recovery of 80% solvent) → Hydrophobic GAC adsorption column (filled with methyl-loaded coal-based carbon, Φ4–8 mm), flow rate 0.5–1.0 m/s, contact time 5–10 seconds → Discharge solvent concentration <10 mg/m³, recovery rate>98%.

VII. Application Process

Taking a penicillin manufacturer (with an annual production capacity of 100 million injections; its fermentation broth contains 30 EU/mL endotoxins and has an active ingredient content of 85%) as a case study—a client of Shanxi Xinhua Carbon Technology Cooperation:

Fermentation broth pretreatment: Penicillin fermentation broth → Plate and frame filtration (to remove mycelium, SS ≤ 5 mg/L) → Ultrafiltration (with a molecular weight cut-off of 10 kDa to remove proteins).

GAC removal of pyrogens: Pre-treated solution → Medical-grade GAC fixed bed (2 units, each containing 8 tons of carbon particles with a diameter of Φ2–5 mm), flow rate 8 m/h, contact time 25 minutes → Endotoxin level <0.08 EU/mL, removal efficiency 99.7%.

Mesoporous GAC purification: From heat source solution → Mesoporous GAC fixed bed (2 units, each containing 10 tons of carbon particles with a diameter of Φ3–6 mm and 50% mesoporous material), flow rate 6 m/h, contact time 25 minutes → Active ingredient content 98.2%, adsorption loss rate 2.5%.

Organic solvent recovery: Synthesis tail gas (methanol 1500 mg/m³) → Condensation (80% recovery) → Hydrophobic GAC adsorption towers (2 units, each containing 5 tons of carbon loaded with Φ4–8 mm methylated coal-based carbon) → Methanol emission <8 mg/m³, recovery rate 98.5%.

Injection filling and sterilization: purified solution → 0.22 μm sterilizing filtration → filling → low-temperature sterilization (100°C, 30 min) → endotoxin <0.1 EU/mL, compliant with Chinese Pharmacopoeia 2020 edition.

Regeneration and Reuse:

After GAC saturation → High-temperature activation (850°C, under N₂ protection) → The adsorption capacity of regenerated carbon is restored to 85% of that of new carbon, at a cost of only 30% of the new carbon's price.

After hydrophobic GAC reaches saturation → Steam desorption (150°C, 0.3 MPa) → Solvent recovery (purity>99%); the regenerated carbon can be reused 3–5 times.

VIII. Application Effects

Following renovation, a penicillin factory achieved significant improvements in key performance indicators (based on actual operational data from Shanxi Xinhua Carbon Technology's partner clients):

metric	Before modification (high-temperature sterilization + condensation)	After modification (medical GAC + mesoporous GAC)	Amplitude Increase	Compliance Status
Endotoxin (EU/mL)	0.8	0.08	Reduce by 90%	China Pharmacopoeia 2020 Edition
Active ingredient content (%):	85	98.2	Increased by 15.5%	European Commission's EU Medicines Agency Guidelines
Active ingredient loss rate (%):	18	2.5	Decreased by 86.1%	—
Methanol recovery rate (%):	40	98.5	Increased by 146.3%	GB 21905-2008
Annual recall loss (in ten thousand yuan)	200	0	Reduce by 100%	—
Annual value of solvent recovery (ten thousand yuan)	0	52	—	—

IX. Core Advantages

For customized solutions tailored for pharmaceutical companies, we offer four irreplaceable advantages:

The product exhibits strong specificity and meets pharmaceutical requirements.

The developed medical-grade GAC (Φ2–5 mm, specific surface area 1000–1200 m²/g, ash content ≤0.5%) is specifically designed to remove endotoxins with a removal rate>99.5%; the mesoporous GAC (with 50% mesopores) exhibits an active ingredient loss rate <3%, with content increased to>98%; the hydrophobic GAC (loaded with methyl groups) achieves a solvent recovery rate>98%. After implementation at a penicillin manufacturer collaborating with Shanxi Xinhua Carbon Technology, the endotoxin compliance rate improved from 85% to 100%.

Safety compliance; comprehensive coverage of all required qualifications.

The product has been certified by the China Pharmacopoeia 2020 edition (medical activated carbon), FDA 21 CFR Part 211 (excipients for injections), and EU EMA guidelines (GMP certification), fully complying with global pharmaceutical industry standards. After being used by a vitamin manufacturer partnered with Shanxi Xinhua Carbon Technology, it passed an on-site audit by the FDA.

Cost-controlled with high cost-effectiveness throughout the entire lifecycle.

Medical GAC: Reusable 3–5 times (with regeneration costs equivalent to 30% of new carbon cost); initial investment ranges from RMB 800,000 to 1.5 million per annual production capacity of 100 million units.

Hydrophobic GAC: provides a solvent recovery value of ¥520,000 per year (as seen in an antibiotic manufacturer), reducing annual environmental fines from ¥300,000 to zero.

X. Cost Analysis

Taking a penicillin injection factory with an annual production capacity of 100 million units as an example, the cost comparison between the activated carbon process and the traditional process is as follows:

project	Medical GAC + Mesoporous GAC + Hydrophobic GAC Process	High-temperature sterilization + condensation + ion exchange process
Initial Investment (Ten Thousand Yuan)	120-200	200-300
Operating Cost (RMB per 10,000 units)	50-80	150-200
Maintenance Cost (RMB 10,000/year)	20-30	50-80
Total Life Cycle Cost (RMB per 10,000 units)	100-150	300-400
Solvent recovery revenue (ten thousand yuan/year)	50-80	0

XI. Why Choose Us?

Performance endorsement: Activated carbon's ability to "eliminate heat sources while preserving active ingredients" has received unanimous acclaim. A penicillin manufacturer, a partner of Shanxi Xinhua Carbon Technology, implemented our medical-grade GAC+ mesoporous GAC; endotoxin levels dropped from 0.8 EU/mL to 0.08 EU/mL, the active ingredient content increased from 85% to 98.2%, and annual recall-related losses were reduced by 2 million yuan.

Technical capabilities: The pore structure has been optimized for pharmaceutical molecules (vitamin B₁₂ ≈ 0.7 nm, cephalosporins ≈ 0.8 nm), resulting in the development of "medical-grade GAC (endotoxin removal rate> 99.5%)" and "GAC with 50% mesoporous fraction (active ingredient loss rate <3%)", addressing the limitations of traditional processes such as incomplete removal of pyrogens and significant loss of active ingredients.

Global Services: With production bases in Shanxi, Ningxia, and Fujian (with an annual capacity of 45,000 tons), we support "customized production + localized distribution." For overseas clients, we provide end-to-end services covering activated carbon selection, process design, and compliance certification (FDA/EMA), ensuring prompt response within 72 hours.​​​​​​​